Meeting
2015 ASCO Annual Meeting
A phase 2 study on efficacy, safety and intratumoral pharmacokinetics of oral selinexor (KPT-330) in patients with recurrent glioblastoma (GBM).
Authors
Ulrik Niels Lassen
Rigshospitalet, Copenhagen, Denmark
Ulrik Niels Lassen , Morten Mau-Soerensen , Andrew L. Kung , Patrick Y. Wen , Eudocia Quant Lee , Scott R. Plotkin , Aida Muhic , Tami Rashal , Tony Williams , Dilara McCauley , Joel Ellis , Jean-Richard Saint-Martin , Robert Carlson , Ran Frenkel , Sharon Shacham , Mansoor Raza Mirza , Michael Kauffman , Andrew B. Lassman
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Central Nervous System Tumors
Clinical Trial Registration Number
NCT01986348
Citation
J Clin Oncol 33, 2015 (suppl; abstr 2044)
DOI
10.1200/jco.2015.33.15_suppl.2044
Abstract #
2044
Poster Bd #
33
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
A phase 1/2 study of selinexor in combination with standard of care therapy for newly diagnosed or recurrent glioblastoma.
First Author: Yazmin Odia
Poster
2019 ASCO Annual Meeting
Phase I/II study of depatuxizumab mafodotin (ABT-414) monotherapy or combination with temozolomide in Japanese patients with/without EGFR-amplified recurrent glioblastoma.
First Author: Yoshitaka Narita
Poster
2015 ASCO Annual Meeting
Preliminary phase II results of selinexor, an oral selective inhibitor of nuclear export in patients with heavily pretreated gynecological cancers.
First Author: Ignace Vergote
Poster
2014 ASCO Annual Meeting
Preclinical and early clinical activity of the oral selective inhibitor of nuclear export (SINE) exportin 1 (XPO1) antagonist KPT-330 (Selinexor) in patients (pts) with platinum-resistant/refractory ovarian cancer (OvCa).
First Author: John Martignetti